18:09 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer Cell culture studies suggest inhibiting KIF15 alone or in combination with KSP could help treat cancer. In HeLa cells, a tool compound KIF15 inhibitor decreased proliferation compared with no treatment, and the KIF15...
07:00 , Oct 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ring finger protein 20 (RNF20); RNF40; kinesin spindle protein (KSP; Eg5; KIF11)

Cancer INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting RNF20 , RNF40 or KSP could help treat breast cancer. In a human breast adenocarcinoma cell line, siRNA targeting RNF20, RNF40 or KSP increased...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Company News

4SC, Link Health deal

4SC granted Link Health exclusive rights to develop and commercialize 4SC-205 in Taiwan and China, including Hong Kong and Macau. Link Health will be responsible for clinical development of the oral inhibitor of kinesin spindle...
01:19 , Jun 1, 2016 |  BC Extra  |  Company News

Link gets China rights to 4SC cancer candidate

4SC AG (Xetra:VSC) granted Link Health Group (Guangzhou, China) exclusive rights to oncology candidate 4SC-205 in China, Hong Kong, Taiwan and Macau. Link Health will be responsible for clinical development of the oral inhibitor of...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Clinical News

4SC-205: Phase I final data

Final data from the open-label, dose-escalation, German Phase I AEGIS trial in 59 patients with advanced solid tumors showed that the recommended Phase II dose of oral 4SC-205 is 20 mg once daily. That dose...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

4SC-205: Phase I data

The open-label, German Phase I AEGIS trial in 46 patients with advanced solid tumors showed that oral 4SC-205 was well tolerated up to the MTD of 150 mg for once-weekly dosing and 75 mg for...
08:00 , Jan 4, 2010 |  BC Week In Review  |  Clinical News

4SC-205: Phase I started

4SC began an open-label, dose-escalation, German Phase I trial to evaluate oral 4SC-205 in up to 30 patients. 4SC AG (Xetra:VSC), Planegg-Martinsried, Germany   Product: 4SC-205   Business: Cancer   Molecular target: Kinesin spindle protein...